Genetic Testing in Recurrent Pancreatitis

When to Pursue Genetic Testing

Genetic testing should be considered in patients with recurrent pancreatitis, particularly when there is a suggestive family history of pancreatic disease or when the etiology remains unexplained after standard workup, as it identifies hereditary pancreatitis and cancer susceptibility genes that fundamentally alter long-term management and cancer surveillance strategies, according to the National Comprehensive Cancer Network 1, 2
Recurrent episodes of pancreatitis with unexplained etiology after standard evaluation should prompt genetic testing, as recommended by Gastroenterology 3

For cancer surveillance implications, genes such as BRCA2, BRCA1, PALB2, ATM should be tested if family history includes pancreatic cancer, as suggested by the National Comprehensive Cancer Network and Gut 1, 2, 4
High-risk genes such as CDKN2A, STK11 require surveillance regardless of family history, according to the National Comprehensive Cancer Network 1, 2
MLH1, MSH2 (Lynch syndrome genes) have a 3.7% lifetime pancreatic cancer risk, as reported by Gut 5, 4

Patients with hereditary pancreatitis (PRSS1 mutations) have approximately a 40% lifetime risk of pancreatic cancer, mandating pancreatic cancer screening starting at age 40 or 20 years after first pancreatitis attack, as recommended by the National Comprehensive Cancer Network and Gut 1, 2, 4
CDKN2A mutation carriers require surveillance starting at age 40 regardless of family history due to 13-22 fold increased pancreatic cancer risk, as reported by Gut and the National Comprehensive Cancer Network 5, 6
STK11 (Peutz-Jeghers) carriers need surveillance beginning at age 30-35, according to the National Comprehensive Cancer Network 1, 7

Genetic testing is not recommended as part of initial workup but should be considered in selected patients after standard evaluation, as stated by Gastroenterology 3
The clinical significance of PRSS1 and SPINK1 variants is unclear without a clinical history of pancreatitis, and therefore germline testing for these genes is generally not recommended unless personal or family history is suggestive of hereditary pancreatitis, as suggested by the National Comprehensive Cancer Network 1, 2

The American College of Medical Genetics and Genomics, as well as other guideline societies, recognize that SPINK1 mutations are associated with an increased risk of chronic pancreatitis and pancreatic cancer, requiring specific surveillance protocols when combined with clinical pancreatitis or family history 8, 9

The National Comprehensive Cancer Network recommends that pancreatic cancer screening in SPINK1 mutation carriers is only recommended when there is a clinical phenotype consistent with hereditary pancreatitis, and should begin at age 40 years, or 20 years after onset of pancreatitis, whichever is earlier 10
Screening should be performed with contrast-enhanced MRI/MRCP and/or endoscopic ultrasound at high-volume centers of expertise, as recommended by the National Comprehensive Cancer Network 10

SPINK1 mutations are recognized as germline mutations associated with varying degrees of increased pancreatic cancer risk, with chronic pancreatitis itself accounting for approximately 5% of pancreatic cancers 8, 9, 11